Hydroxybisphosphonate bound doxorubicin - Atlanthera
Alternative Names: 12b80; 12B80-HBP-BOUND DOXORUBICIN; hbp bound doxorubicinLatest Information Update: 04 Oct 2022
At a glance
- Originator Atlanthera
- Class Anthracenes; Antineoplastics; Bisphosphonates; Cytostatic antibiotics; Small molecules
- Mechanism of Action Bone resorption factor inhibitors; DNA cross linking agents; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Chondrosarcoma; Ewing's sarcoma; Osteosarcoma
Most Recent Events
- 04 Oct 2022 Atlanthera plans for clinical trial for hydroxy bisphosphonate bound doxorubicin (Atlanthera pipeline, September 2022)
- 26 Sep 2022 Atlanthera has filed patent application covering hydroxy bisphosphonate bound doxorubicin (Atlanthera pipeline, September 2022)
- 26 Sep 2022 Preclinical trials in Chondrosarcoma in France (unspecified route)